Latest Aktis Oncology News & Updates

See the latest news and media coverage for Aktis Oncology. We track all announcements, press releases, and industry mentions in real time, all in one place.

Aktis Oncology

Biotechnology company developing targeted alpha radiopharmaceuticals

aktisoncology.com

Company type: Public company
Number of employees: 90–200

Last updated Today

Latest news about Aktis Oncology

In short: Aktis Oncology raised $318 million in an initial public offering and advanced its clinical pipeline for targeted radiopharmaceuticals.

Company announcements

May 22 Aktis Oncology

Aktis Oncology reports first-in-human imaging data for AKY-2519

Data show robust tumor uptake and limited normal tissue exposure in B7-H3 expressing tumors, with potential differentiated profile.

May 4 Aktis Oncology

Aktis Oncology reports Q1 2026 financial results and highlights

Following its IPO, the company reported a net loss of $18.3 million, cash of $538.5 million, and clinical trial initiations for AKY-2519.

March 30 Aktis Oncology

Aktis Oncology announces FDA clearance for AKY-2519 and 2025 results

AKY-2519, a miniprotein radioconjugate targeting B7-H3, will enter Phase 1b mid-2026; pro forma cash $562M.

February 24 Aktis Oncology

Aktis Oncology has received FDA Fast Track designation for AKY-1189

It is for treating locally advanced or metastatic urothelial cancer after prior therapies. A Phase 1b trial is ongoing.

Media coverage

May 21 MENAFN

Aktis Oncology Reports First-In-Human Clinical Imaging And Dosimetry Data For AKY-2519 Demonstrating Robust Tumor Uptake And Limited Normal Tissue Exposures In Patients With B7 ...

Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Combined results evaluating AKY-2519 across several B7-H3...

April 21 WFMZ

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...

March 30 Yahoo Finance

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...

February 23 Yahoo Finance

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...

Never miss news about Aktis Oncology

Track Aktis Oncology and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.